Patents by Inventor Frederick BARR

Frederick BARR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACTION OF L-CITRULLINE TO PREVENT OR TREAT ENDOTHELIAL DYSFUNCTION
    Publication number: 20250170084
    Abstract: This invention provides methods for treating endothelial dysfunction by administering an effective amount of citrulline to a patient. The patients may be suffering from acute respiratory distress syndrome (ARDS), sepsis, or infection by COVID-19 (Coronavirus Disease 2019); COVID-19 patients may be at risk of developing endothelial dysfunction, or they may be experiencing endothelial dysfunction. The effective amount of citrulline is sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) or to reduce the formation of free radicals. Citrulline may be administered orally; intravenously; or both orally and intravenously in a sequential manner. Sequential administration of citrulline may be in three phases, such as (a) an initial phase in which citrulline is administered orally, (b) an intermediate phase wherein citrulline is administered intravenously, and (c) a final phase wherein citrulline is administered orally.
    Type: Application
    Filed: July 19, 2024
    Publication date: May 29, 2025
    Inventors: Gurdyal KALSI, Frederick Barr, Gary Pasternack, Marshall Summar
  • Action of L-citrulline to prevent or treat endothelial dysfunction
    Patent number: 12064409
    Abstract: This invention provides methods for treating endothelial dysfunction by administering an effective amount of citrulline to a patient. The patients may be suffering from acute respiratory distress syndrome (ARDS), sepsis, or infection by COVID-19 (Coronavirus Disease 2019); COVID-19 patients may be at risk of developing endothelial dysfunction, or they may be experiencing endothelial dysfunction. The effective amount of citrulline is sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) or to reduce the formation of free radicals. Citrulline may be administered orally; intravenously; or both orally and intravenously in a sequential manner. Sequential administration of citrulline may be in three phases, such as (a) an initial phase in which citrulline is administered orally, (b) an intermediate phase wherein citrulline is administered intravenously, and (c) a final phase wherein citrulline is administered orally.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: August 20, 2024
    Assignees: VANDERBILT UNIVERSITY, ASKLEPION PHARMACEUTICALS, LLC
    Inventors: Gurdyal Kalsi, Frederick Barr, Gary Pasternack, Marshall Summar
  • ACTION OF L-CITRULLINE TO PREVENT OR TREAT ENDOTHELIAL DYSFUNCTION
    Publication number: 20220401396
    Abstract: This invention provides methods for treating endothelial dysfunction by administering an effective amount of citrulline to a patient. The patients may be suffering from acute respiratory distress syndrome (ARDS), sepsis, or infection by COVID-19 (Coronavirus Disease 2019); COVID-19 patients may be at risk of developing endothelial dysfunction, or they may be experiencing endothelial dysfunction. The effective amount of citrulline is sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) or to reduce the formation of free radicals. Citrulline may be administered orally; intravenously; or both orally and intravenously in a sequential manner. Sequential administration of citrulline may be in three phases, such as (a) an initial phase in which citrulline is administered orally, (b) an intermediate phase wherein citrulline is administered intravenously, and (c) a final phase wherein citrulline is administered orally.
    Type: Application
    Filed: June 30, 2021
    Publication date: December 22, 2022
    Inventors: Gurdyal KALSI, Frederick BARR, Gary PASTERNACK, Marshall SUMMAR